| Lightcalls.com |
|
|
![]() |
hardly any scientific breakthroughs...hardly any scientific breakthroughs have occurred with Alzheimer's disease since 1907 when Alois Alzheimer first identified brain changes characteristic of the progressive mental disease that now bears his name. That is, until recently Several major studies have been published from one side of to the other the past 12 months offering a ray of expectancy to families affected by this devastating illness. Perhaps the inundate of new research can be traced to the burgeoning legions of Baby Boomer heading into their older years, and fearful of the many age-related illnesses that nature could have in store. First, there was the announcement from the Alzheimer's Disease Cooperative cogitation that high doses of vitamin E (2000 I.U. by day) over a two-year period saves the day-to-day basic functioning capability of those afflicted with the mind-robbing disease of Alzheimer's. Now there's the research at handed at an American Medical Association conversation showing that the ancient herb Ginkgo biloba ("ginkgo") helps keep reasoning, memory, and behavior in Alzheimer's patients. Understanding Alzheimer's disease An estimated four million Americans are afflicted with Alzheimer's disease; in fact, it is the fourth leading cause of death among adults, accounting for about 10000 deaths each year. Although this mortality rate is alarming, the chiefly tragic aspect of Alzheimer's disease is the los of memory, reasoning power, and ability to carry abroad daily functions that Alzheimer's victims undergo in the years -- and sometimes decades -- before death. The los of cognitive function is known as dementia, a condition that is primarily associated with Alzheimer's disease. Antioxidant nutrients, on disarming free radicals before they damage clew cell components, can act as "antidotes" to the delivered radical-induced changes that may introduce Alzheimer's disease. In fact, the pair recent studies demonstrating that vitamin E and ginkgo aid Alzheimer's patients share an underlying commonality: the couple of these nutrients are antioxidants. religious news about ginkgo Ginkgo biloba is the oldest living species of tree and ginkgo leaves have been used medicinally for at least 5000 years for the treatment of memory los in the somewhat advanced in life among other benefits. Modern research now confirms this ancient application for ginkgo. According to Pierre Le Bars, PhD MD and associate researchers from the New York Institute for Medical Research, almost one-third of Alzheimer's patients taking ginkgo postscripts showed improvements in cognitive function during a double-blind clinical trial comparing ginkgo supplys with a placebo. Le Bars' consideration enrolled 327 patients with dementia (caused by the agency of either Alzheimer's disease or stroke) and randomly assigned them to take either ginkgo correlatives or look-alike placebo pills each day for one year. The ginkgo appendixs provided 120 mg of a standardized concentrated extract known as EGb Of the initially listed group, only 137 patients complet the entire meditation -- some patients were dropp from the reflection because they developed other, unrelated illnesses, any did not take the scheduled amounts of add tos and others were withdrawn from the meditation by their caregivers. application of mind results show improvement After about six month of daily supply use, the ginkgo group showed better conclusions on standard tests of reasoning, memory, and behavior. Meanwhile, the assemblage taking placebos showed worsening touchstone results, which would be reckon uponed with the progressive nature of Alzheimer's disease. In other words, Le Bars explains that "EGb appears to stabilize And, in an additional 20 percent of cases v placebo), improve the patient's functioning for periods of six month to single year. Regarding its safety, adverse general intents associated with EGb were no different from those associated with [the] placebo." to what degree does it do it? Well, according to Le Bars, and colleagues, "the mechanism of action of" ginkgo is "only partially understood," although the main drifts seem to be related to its antioxidative properties, involving mingle families in the herb, including flavonoids, terpenoids (ginkgolides, bilobalide), and organic acids. REFERENCES Le Bars, PL Katz, MM Berman, N et al. "A placebo-controlled, double-blind, randomized trial of an extract of ginkgo biloba for dementia," JAMA 278(16):1327-1332 1997 Drachman, D.A., and Leber, P "Treatment of Alzheimer's disease -- Searching for a breakthrough, settling for less" novel Engl J Med 336:1245-47,1997. COPYRIGHT 1998 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |